| 王 玮,白俊文,杨俊杰,等.HER2低表达对早期乳腺癌预后的影响分析[J].肿瘤学杂志,2024,30(1):25-31. |
| HER2低表达对早期乳腺癌预后的影响分析 |
| Association of HER2 Expression Levels with Clinicopathological Features and Prognosis in Patients with Early Breast Cancer |
| 投稿时间：2023-05-21 |
| DOI：10.11735/j.issn.1671-170X.2024.01.B006 |
|
 |
| 中文关键词: 乳腺癌 HER2低表达 临床病理特征 预后 |
| 英文关键词:breast cancer HER2 low expression clinicopathological feature prognosis |
| 基金项目:内蒙古自治区高等学校科学研究项目（NJZY22642） |
|
| 摘要点击次数: 127 |
| 全文下载次数: 60 |
| 中文摘要: |
| 摘 要： ［目的］ 比较早期乳腺癌中不同人表皮生长因子受体2(human epidermal growth factor receptor 2，HER2)蛋白表达患者的临床病理特征及预后的差异性。［方法］ 收集2010年6月至2019年6月内蒙古医科大学附属医院甲状腺乳腺外科收治的792例Ⅰ~Ⅱ期乳腺癌患者的临床病理资料，入组患者根据HER2蛋白表达水平分为HER2不表达301例、HER2低表达309例、HER2阳性182例三组，回顾性分析不同HER2亚组患者临床病理特征及预后的差异性。［结果］ HER2低表达患者主要以Luminal A型为主，三阴性乳腺癌（triple-negative breast cancer，TNBC）所占比例较低。与HER2不表达患者相比，HER2低表达患者腋窝淋巴结阳性、脉管癌栓及激素受体（hormone receptor，HR）阳性所占比例较高，浸润性小叶癌、组织学分级以及Ki-67高表达所占比例较低。共随访792例患者，中位随访时间为56个月，HER2阳性、HER2低表达、HER2不表达患者5年无病生存率（disease free survival，DFS）分别为85.7%、92.9%、91.3%（?字2＝8.268，P＝0.016），5年总生存率（overall survival，OS）分别为92.8%、97.4%、96.8%（?字2＝15.809，P<0.001），按HR状态分层分析后5年DFS差异也无统计学意义。［结论］ 虽然HER2低表达乳腺癌具有独特的临床病理特征，但并未导致HER2低表达和HER2不表达乳腺癌预后差异。研究结果支持HER2低表达乳腺癌作为独立的生物学亚型。 |
| 英文摘要: |
| Abstract： ［Objective] To compare the clinicopathological features and prognosis in early breast cancer patients with different human epidermal growth factor receptor 2(HER2) protein expression levels. ［Methods] The clinicopathological data of 792 patients with stageⅠ~Ⅱbreast cancer admitted to the Department of Thyroid and Breast Surgery of Affiliated Hospital of Inner Mongolia Medical University from June 2010 to June 2019 were retrospectively analyzed， including 301 cases of HER2 zero expression， 309 cases of HER2 low expression and 182 cases of HER2 positive. The clinicopathological features and prognosis among three groups were compared. ［Results] There were significant differences in proportions of histological and molecular subtypes and clinicopathological features among three groups. Patients with HER2 low expression had higher proportion of Luminal A subtype， and lower proportion of triple-negative breast cancer (TNBC). Compared with patients with HER2 zero expression， patients with HER2 low expression had a higher proportion of positive axillary lymph nodes， lympho-vascular invasion and hormone receptor(HR) positive， and a lower proportion of invasive lobular carcinoma， high histological grade and high Ki-67 expression. A total of 792 patients were followed up with median follow-up time 56 months. The 5-year disease free survival (DFS) of patients with positive expression of HER2， low expression of HER2， and zero expression of HER2 were 85.7%， 92.9%， and 91.3%， respectively (?字2=8.268， P=0.016)， 5-year overall survival (OS) were 92.8%， 97.4%， 96.8%(?字2=15.809， P<0.001)， respectively. There was no significant difference in 5 years DFS at after stratified analysis by HR status. ［Conclusion] HER2 low expression breast cancer has unique clinicopathological features， but there is no significant difference in prognosis between of patients with HER2 low expression and HER2 zero expression， so this study does not support low HER2 breast cancer as an independent biological subtype. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |